Everything Dolinnov, in one place.
The team’s cockpit for DOL-001 — our non-opioid FXYD2 lipid-ASO for chronic pain.
Open grant calls
8+2
Competitors profiled
14ASO / siRNA
Bibliography references
41+41 new
Next deadline
EurostarsFeb
Tools
Open allGrants tracker
Pipeline, timeline, aims coverage, deadlines & deliverables (EIC, Eurostars, CDMRP).
Competitive watch
Who else is chasing ASO / siRNA pain — science, data quality & IP.
Pharma mapping
Target pharmas by indication, deep cards, signals & decision-makers.
Bibliography
Every key paper, tagged by thesis pillar and ready to cite in a data room.
Dolia digests
The weekly non-opioid pain-watch — automated digest, searchable archive.
Redmontis
Financial follow-up & reporting platform, developed externally.
What’s new
- Bibliography live — 41 references, categorised in Airtable.
- Board deck v3 uploaded to the data room.
- Eurostars pre-proposal due February.
Recent additions · Bibliography
FXYD2 antisense oligonucleotide — chronic painDolinnov2023
QV2421 — NaV1.7 ASO (Quiver)External2026
NaV1.8 abrogation limits in DRG neuronsExternal2025
LNP-siRNA delivery to DRG (Woolf)External2025
Gated by Dolinnov SSO (Entra ID) · Phase 0 mockup — sample figures & copy.